Boehringer Ingelheim has stressed its commitment to tackling mental illness, as it is "one of the greatest health, social and economic challenges of our time".
The pharmaceutical company noted that there is still no cure for Alzheimer's disease and "little in the way of treatments", despite intensive efforts over the years.
“Boehringer Ingelheim has said it is determined to progress a deeper understanding of the brain pathways impacting mental illness.“
However, it stressed that it is "determined to progress a deeper understanding of the brain pathways impacting mental illness", particularly as it is a supporter of the European Federation of Pharmaceutical Industries and Associations' 'We won't rest' initiative.
The company was speaking after it confirmed that its Phase II Alzheimer's disease trials with investigational compound BI 409306 had not met its efficacy endpoints and plans for further trials with BI 409306 in AD will therefore not be pursued.
Nevertheless, Boehringer Ingelheim will "refocus efforts on the ongoing schizophrenia trials with this compound".
Jan Poth, therapeutic area head of CNS Diseases at Boehringer Ingelheim, commented: "Disappointments are a daily experience in science, but even these clinical trial results will add to the understanding of brain function and contribute to future progress in this area."
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.See all the latest jobs in Pharmaceutical